Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1967-1975

  Song, Eun Kee ^a,b   Tai, W M ^a   Messersmith, Wells A ^a   Bagby, Stacey ^a   Purkey, Alicia ^a   Quackenbush, Kevin S ^a   Pitts, Todd M ^a   Wang, Guoliang ^a   Blatchford, Patrick ^a   Yahn, Rachel ^a   Kaplan, Jeffrey ^a   Tan, Aik Choon ^a   Atreya, Chloe E ^c   Eckhardt, Gail ^a   Kelley, Robin K ^c   Venook, Alan ^c   Kwak, Eunice L ^d   Ryan, David ^d   Arcaroli, John J ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Chonbuk National University Medical School and Hospital   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; C MET; Colorectal cancer; PIK3CA; RET; VEGFR2

Indexed keywords

CABOZANTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANGIOGENESIS INHIBITOR; ANILIDE; ANTINEOPLASTIC AGENT; PIK3CA PROTEIN, HUMAN; PYRIDINE DERIVATIVE; SCATTER FACTOR RECEPTOR; TUMOR MARKER; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PIK3CA GENE; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR VOLUME; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; HCT116 CELL LINE; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922567957     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29225     Document Type: Article

References (42)

1. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69 Suppl 3:4-10.
2. Hubbard J, Grothey A. Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol 2010;22:374-80.
3. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37.
4. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 2013;381:303-12.
5. Di Tomaso E, Snuderl M, Kamoun WS, et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 2011;71:19-28.
6. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
7. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
8. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70:10090-100.
9. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nature reviews Cancer 2012;12:89-103.
10. Takeuchi H, Bilchik A, Saha S, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003;9:1480-8.
11. Raghav KPS, Amin HM, Wang W, et al. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. J Clin Oncol 2013;31: Abstract 3529.
12. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-73.
13. Navis AC, Bourgonje A, Wesseling P, et al. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PLoS One 2013;8:e58262.
14. Nguyen HM, Ruppender N, Zhang X, et al. Cabozantinib inhibits growth of and rogensensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One 2013;8:e78881.
15. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-61.
16. Dangles-Marie V, Pocard M, Richon S, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 2007;67:398-407.
17. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-50.
18. Kanehisa M, Araki M, Goto S, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008;36:D480-4.
19. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308.
20. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2:270-87.
21. Bentzien F, Zuzow M, Heald N, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid 2013;23:1569-77.
22. Hage C, Rausch V, Giese N, et al. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis 2013;4:e627.
23. Graham TJ, Box G, Tunariu N, et al. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst 2014;106: dju033.
24. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91.
25. Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010;10:575-85.
26. Moserle L, Jimenez-Valerio G, Casanovas O. Antiangiogenic therapies: going beyond their limits. Cancer Discov 2014;4:31-41.
27. Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010;16:5936-41.
28. Verma A, Warner SL, Vankayalapati H, et al. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther 2011;10:1763-73.
29. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
30. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48.
31. Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678-82.
32. Wang R, Ferrell LD, Faouzi S, et al. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001;153:1023-34.
33. Yu Y, Merlino G. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res 2002;62:2951-6.
34. Dunne PD, McArt DG, Blayney JK, et al. AXL is a key regulator of inherent and chemotherapyinduced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin Cancer Res 2014;20:164-75.
35. Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusionpositive lung adenocarcinomas. Cancer Discov 2013;3:630-5.
36. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6.
37. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-62.
38. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41:1649-54.
39. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI (3) K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122:2255-9.
40. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
41. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65:4562-7.
42. Corcoran RB, Ebi H, Turke AB, et al. EGFRmediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35.